Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

LogicBio Therapeutics

Nasdaq:LOGC
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LOGC
Nasdaq
$122M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • LogicBio Therapeutics has significant price volatility in the past 3 months.
LOGC Share Price and Events
7 Day Returns
-1.3%
NasdaqGM:LOGC
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-46.9%
NasdaqGM:LOGC
0%
US Biotechs
-11.5%
US Market
LOGC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
LogicBio Therapeutics (LOGC) -1.3% -34.8% -26% -46.9% - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • LOGC underperformed the Biotechs industry which returned 0% over the past year.
  • LOGC underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is LogicBio Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for LogicBio Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $5.25.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for LogicBio Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are LogicBio Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:LOGC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.78
NasdaqGM:LOGC Share Price ** NasdaqGM (2020-03-27) in USD $5.25
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of LogicBio Therapeutics.

NasdaqGM:LOGC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:LOGC Share Price ÷ EPS (both in USD)

= 5.25 ÷ -1.78

-2.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • LogicBio Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • LogicBio Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does LogicBio Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:LOGC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.96x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for LogicBio Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on LogicBio Therapeutics's assets?
Raw Data
NasdaqGM:LOGC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.84
NasdaqGM:LOGC Share Price * NasdaqGM (2020-03-27) in USD $5.25
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:LOGC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:LOGC Share Price ÷ Book Value per Share (both in USD)

= 5.25 ÷ 1.84

2.86x

* Primary Listing of LogicBio Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • LogicBio Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess LogicBio Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. LogicBio Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is LogicBio Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LogicBio Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is LogicBio Therapeutics expected to grow at an attractive rate?
  • Unable to compare LogicBio Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare LogicBio Therapeutics's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare LogicBio Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:LOGC Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:LOGC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:LOGC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 162 2
2023-12-31 48 2
2022-12-31 0 2
2021-12-31 0 3
2020-12-31 0 3
2020-03-28
NasdaqGM:LOGC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -39 -40
2019-09-30 -32 -32
2019-06-30 -26 -25
2019-03-31 -20 -20
2018-12-31 -15 -18
2018-09-30 -13 -18
2018-06-30 -11 -11
2018-03-31 -8 -9
2017-12-31 -6 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if LogicBio Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if LogicBio Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:LOGC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from LogicBio Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:LOGC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28
NasdaqGM:LOGC Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.78
2019-09-30 -1.50
2019-06-30 -1.55
2019-03-31 -1.87
2018-12-31 -3.04
2018-09-30 -9.69
2018-06-30 -6.48
2018-03-31 -5.73
2017-12-31 -5.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if LogicBio Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine LogicBio Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. LogicBio Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. LogicBio Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess LogicBio Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
LogicBio Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has LogicBio Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare LogicBio Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • LogicBio Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare LogicBio Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare LogicBio Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
LogicBio Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from LogicBio Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:LOGC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -40.13 10.39 30.66
2019-09-30 -31.77 9.74 27.24
2019-06-30 -24.85 9.69 20.82
2019-03-31 -20.41 8.58 15.11
2018-12-31 -17.62 6.86 11.08
2018-09-30 -18.20 5.45 8.20
2018-06-30 -11.13 3.80 6.35
2018-03-31 -8.79 2.80 4.57
2017-12-31 -7.74 2.30 3.56
2016-12-31 -3.77 1.37 2.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if LogicBio Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if LogicBio Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if LogicBio Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess LogicBio Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
LogicBio Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is LogicBio Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up LogicBio Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • LogicBio Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • LogicBio Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of LogicBio Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from LogicBio Therapeutics Company Filings, last reported 2 months ago.

NasdaqGM:LOGC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 42.29 9.81 50.65
2019-09-30 53.20 9.76 63.16
2019-06-30 63.41 0.00 63.66
2019-03-31 72.82 0.00 72.54
2018-12-31 80.23 0.00 80.91
2018-09-30 14.45 0.00 12.88
2018-06-30 18.81 0.00 18.26
2018-03-31 24.46 0.00 24.58
2017-12-31 24.46 0.00 24.58
2016-12-31 1.11 0.00 1.73
  • LogicBio Therapeutics's level of debt (23.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if LogicBio Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • LogicBio Therapeutics has sufficient cash runway for 1.3 years based on current free cash flow.
  • LogicBio Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 71.3% each year.
X
Financial health checks
We assess LogicBio Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. LogicBio Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is LogicBio Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from LogicBio Therapeutics dividends.
If you bought $2,000 of LogicBio Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate LogicBio Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate LogicBio Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:LOGC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:LOGC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as LogicBio Therapeutics has not reported any payouts.
  • Unable to verify if LogicBio Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of LogicBio Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as LogicBio Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess LogicBio Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can LogicBio Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. LogicBio Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of LogicBio Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Fred Chereau
COMPENSATION $1,599,916
AGE 52
TENURE AS CEO 3.9 years
CEO Bio

Mr. Frederic Chereau, also known as Fred, M.B.A., is the President and Chief Executive Officer of LogicBio Therapeutics, Inc. since April 2016 and serves as its Director. He served as the President and Chief Operating Officer of aTyr Pharma Inc. from February 05, 2014 to July 13, 2015. Mr. Chereau served as Senior Vice President at Shire plc since September 2012, where he had worldwide strategic and financial responsibility for the overall franchise activities. Mr. Chereau served as Senior Vice President and Franchise Lead of Angioedema Franchise at Shire Human Genetic Therapies Inc., since September 2012. Mr. Chereau oversaw the development and execution of the global strategy for the angioedema franchise. He served as Chief Executive Officer and President of Pervasis Therapeutics, Inc. since October 2008, where he led it through key strategies for operational, business development portfolio and R&D refinement. Mr. Chereau served as Vice President and General Manager of Genzyme Cardiovascular (CV), a business unit within Genzyme Corporation in Cambridge. He was responsible for launching and commercializing a hypercholesterolemia product (Cholestagel(R) - colesevelam) outside of the US and oversaw late clinical stage gene therapy program in Peripheral Arterial Disease and various stage programs. He also led Genzyme's cardiovascular business development activities, including and its in-licensing transaction with ISIS Pharmaceuticals. Mr. Chereau held various positions within Genzyme in Europe and in the US culminating in his position at Genzyme CV since 2006. He also served as the Chief Operating Officer of MG Biotherapeutics LLC, a Genzyme and Medtronic joint-venture formed to develop cellular therapies for cardiac repair. He held sales and marketing positions at a French medical device retail company in the hemodialysis field. He began his career with Hemotech in France where he held various sales and marketing positions. Mr. Chereau worked at Genzyme from 1999 to 2008, where he held roles with increasing responsibility initially within Genzyme France and Genzyme Europe. He serves as a Director of Pervasis Therapeutics, Inc. He is a Member of the Board of Directors of the French American Chamber of Commerce of New England and a Member of Strategic Advisory Board of the La Rochelle Business School. He is fluent in both French and English. Mr. Chereau holds a Bachelor's degree in Physics from Paris University, completed Master's Degree in Business Administration at the La Rochelle Business School, and received Executive MBA from INSEAD.

CEO Compensation
  • Fred's compensation has increased whilst company is loss making.
  • Fred's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the LogicBio Therapeutics management team in years:

1.8
Average Tenure
51
Average Age
  • The average tenure for the LogicBio Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Fred Chereau

TITLE
President
COMPENSATION
$2M
AGE
52
TENURE
3.9 yrs

Mark Kay

TITLE
Co-Founder & Director
COMPENSATION
$235K
AGE
61

Leszek Lisowski

TITLE
Co-Founder

Adi Barzel

TITLE

Matthias Jaffé

TITLE
CFO & Treasurer
COMPENSATION
$189K
AGE
50
TENURE
2.5 yrs

Matthias Hebben

TITLE
Global VP & Head of Technology Development
TENURE
0.9 yrs

Seokho Yoon

TITLE
Chief Administrative Officer
AGE
41
TENURE
0.3 yrs

Brian Luque

TITLE
Associate Director of Investor Relations

Tom Wilton

TITLE
Chief Business Officer
COMPENSATION
$459K
AGE
44
TENURE
2.5 yrs

Ken Huttner

TITLE
Senior VP & Head of Clinical Development
AGE
66
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the LogicBio Therapeutics board of directors in years:

3.5
Average Tenure
55
Average Age
  • The tenure for the LogicBio Therapeutics board of directors is about average.
Board of Directors

Mark Kay

TITLE
Co-Founder & Director
COMPENSATION
$235K
AGE
61
TENURE
4.2 yrs

Leon Chen

TITLE
Independent Director
COMPENSATION
$164K
AGE
43
TENURE
4.2 yrs

Fred Chereau

TITLE
President
COMPENSATION
$2M
AGE
52

Mike Wyzga

TITLE
Independent Director
COMPENSATION
$165K
AGE
64
TENURE
1.5 yrs

Richard Moscicki

TITLE
Independent Director
COMPENSATION
$163K
AGE
67
TENURE
1.4 yrs

Erez Chimovits

TITLE
Independent Director
COMPENSATION
$164K
AGE
55
TENURE
4.2 yrs

Daniel O'Connell

TITLE
Independent Director
COMPENSATION
$163K
AGE
40
TENURE
2.8 yrs

Mark Enyedy

TITLE
Director
AGE
55
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess LogicBio Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. LogicBio Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Shareholders Own LogicBio Therapeutics, Inc. (NASDAQ:LOGC)?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … LogicBio Therapeutics is a smaller company with a market capitalization of US$215m, so it may still be flying under the radar of many institutional investors. … Check out our latest analysis for LogicBio Therapeutics

Simply Wall St -

Company Info

Description

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate Lb-301 for the treatment of crigler-najjar syndrome. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Details
Name: LogicBio Therapeutics, Inc.
LOGC
Exchange: NasdaqGM
Founded: 2014
$122,323,472
23,299,709
Website: http://www.logicbio.com
Address: LogicBio Therapeutics, Inc.
99 Erie Street,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM LOGC Common Stock Nasdaq Global Market US USD 19. Oct 2018
DB 0IF Common Stock Deutsche Boerse AG DE EUR 19. Oct 2018
Number of employees
Current staff
Staff numbers
41
LogicBio Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 04:14
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/17
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.